Evidence map›Paper›PMID 34457111›Full record

ArticleOxidative medicine and cellular longevity2021

Irisin Attenuates Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis in the H9C2 Cellular Model of Septic Cardiomyopathy through Augmenting Fundc1-Dependent Mitophagy.

Xiaoqing Jiang, Shumin Cai, Yinghui Jin, Feng Wu, Jing He, Xixuan Wu, Ying Tan, Yu Wang

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 76 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Role of irisin in bone diseases.Frontiers in endocrinology · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xiaoqing JiangDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Shumin CaiDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Yinghui JinDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Feng WuDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Jing HeDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Xixuan WuDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Ying TanDepartment of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.ORCID https://orcid.org/0000-0001-6469-8338
Yu WangDepartment of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.ORCID https://orcid.org/0000-0001-7060-2953
Nanfang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, we used lipopolysaccharide- (LPS-) stimulated H9C2 cardiomyocytes to investigate whether irisin treatment attenuates septic cardiomyopathy via Fundc1-related mitophagy. Fundc1 levels and mitophagy were significantly reduced in LPS-stimulated H9C2 cardiomyocytes but were significantly increased by irisin treatment. Irisin significantly increased ATP production and the activities of mitochondrial complexes I and III in the LPS-stimulated cardiomyocytes. Irisin also improved glucose metabolism and significantly reduced LPS-induced levels of reactive oxygen species by increasing the activities of antioxidant enzymes, glutathione peroxidase (GPX), and superoxide dismutase (SOD), as well as levels of reduced glutathione (GSH). TUNEL assays showed that irisin significantly reduced LPS-stimulated cardiomyocyte apoptosis by suppressing the activation of caspase-3 and caspase-9. However, the beneficial effects of irisin on oxidative stress, mitochondrial metabolism, and viability of LPS-stimulated H9C2 cardiomyocytes were abolished by silencing Fundc1. These results demonstrate that irisin abrogates mitochondrial dysfunction, oxidative stress, and apoptosis through Fundc1-related mitophagy in LPS-stimulated H9C2 cardiomyocytes. This suggests irisin is a potentially useful treatment for septic cardiomyopathy, though further investigations are necessary to confirm our findings.

Indexed as

ApoptosisOxidative StressAnimalsCardiomyopathiesCells, CulturedFibronectinsMembrane ProteinsMitochondriaMitochondrial ProteinsMitophagyMyocytes, CardiacRatsSepsisFibronectinsFNDC5 protein, ratFUNDC1 protein, ratMembrane ProteinsMitochondrial Proteins

Identifiers

PMID34457111
PMCPMC8390168
OpenAlexW3194171624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.